(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 115.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Mesoblast's revenue in 2025 is $17,198,000.On average, 2 Wall Street analysts forecast MESO's revenue for 2026 to be $78,250,793,977, with the lowest MESO revenue forecast at $68,183,852,051, and the highest MESO revenue forecast at $88,317,735,903.
In 2027, MESO is forecast to generate $149,756,160,879 in revenue, with the lowest revenue forecast at $149,756,160,879 and the highest revenue forecast at $149,756,160,879.